Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Does high risk cytogenetics as a sole abnormality influence your treatment decision for smoldering multiple myeloma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Harvard Medical School

Several studies have looked at the prognostic factor of FISH abnormalities and risk of progression of SMM to active disease (Neben et al., 2013; Rajkumar et al., 2013). Deletion 17p and t(4;14) are associated with the highest risk of progression, with median time to progression of 24 months, as repo...

Would you hold immunotherapy if a patient with metastatic melanoma has stable disease for 6 months?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Institut Gustave Roussy

We would usually not stop therapy in a patient with a stable disease as best response after only 6 months. In Keynote 006, patients had to stop therapy after 2 years of treatment. In this trial, 12 patients were in stable disease after 2 years. Ten of them were still in stable disease after 9 months...

How do you approach treatment of a glioblastoma in pregnancy?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Louisville School of Medicine

Glioblastoma during pregnancy could be treated safely (to mother and fetus) with certain precautions and modifications. Collaboration and consultation with the patient’s obstetrician are essential. External shielding over the patient’s abdomen during treatment will decrease the external scatter radi...

What is the recommended follow-up/surveillance schedule following organ preservation treatment approach for cT1-2N0 rectal cancer?

3
2 Answers

Mednet Member
Mednet Member
Medical Oncology · OHSU Knight-Legacy Health Cancer Collaborative

Patients with stage I rectal cancer treated with organ preservation require close surveillance to rule out tumor regrowth and local recurrence that may be salvaged with radical surgery. The highest risk of recurrence is within 2 years after completion of neoadjuvant therapy and patients should be fo...

How do you approach and counsel women with high risk, early stage breast cancer requiring chemotherapy for whom fertility preservation is a major concern?

6
2 Answers

Mednet Member
Mednet Member
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida

Fertility preservation is a major issue in survivorship for younger cancer patients. Discussion with a specialist regarding banking eggs or embryos as early as possible is important. Proven techniques such as embryo cryopreservation may not be available due to financial constraints or other issues. ...

Is pembrolizumab considered standard of care in the 2nd line treatment of recurrent cervical cancer?

1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · University of California Irvine Medical Center

The phase II Keynote-158 indication is based on objective response of 14% in patients with PD-L1+ tumors. The US FDA approval is accelerated approval meaning that there needs to be a confirmatory trial - this is Keynote 826 which is ongoing.

When and how are you incorporating tumor sequencing to plan treatment of metastatic prostate cancer?

4
5 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

Presently, the main categories of actionable DNA based alterations in advanced prostate cancer are 1) alterations in homologous repair enzymes like BRCA2, and 2) microsatellite instability (MSI high status, mismatch repair gene deficiency). These are actionable as they can lead to the use of a thera...

Do you refer all of your patients for EGD prior to initiation of atezolizumab/bevacizumab for advanced HCC?

4 Answers

Mednet Member
Mednet Member
Medical Oncology · Geffen School of Medicine at UCLA

Per the trial, this was required within 6 months of starting the study. However, in practice, I don't know that this strict rule would be necessary. For example, what if an EGD was done 10 months ago without varices? I don't think I would feel strongly about this. Similarly, if we could get one shor...

Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Infliximab and methotrexate are generally used in irAE grades 3 or 4, or in grade 2 irAEs that are refractory to initial treatment with steroids. Methotrexate is typically used for irAEs of the musculoskeletal system, such as inflammatory arthritis or myositis. Infliximab tends to be used in the set...

For women who have had either embryo or oocyte cryopreservation, do you also recommend administering GnRH analogs?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Dana-Farber Cancer Institute

For anyone who is interested in fertility preservation enough to undergo egg or embryo cryopreservation, I think offering GnRH analog treatment through chemotherapy for prevention of premature ovarian insufficiency and potentially infertility makes sense. Although some women may not want to deal eve...